We do. Van Heron Labs reads your cells at multi-omic depth, builds a comprehensive biological digital twin, and translates their physiology into decisions — media, feed, process, and manufacturing outcomes. Then our team delivers what those insights recommend, from analytics through commercial scale.
Every engagement starts with reading your cells and ends with a delivered improvement to your process, product, or program. Not analytics for its own sake — decisions and materials you can put to work.
Mechanism-backed process modifications and feed strategies that improve titer, viability, and CQAs.
Full formulations designed from cellular data, with complete ingredient transparency and IP flexibility.
Targeted CD supplements and specific-biologic feed strategies designed for your cell system and process or as new products you can sell commercially.
Multi-omic characterization of cells, cultures, and ancillary materials — the highest-resolution picture available.
Head-to-head evaluations across cell types, processes, or reagent prototypes — with mechanism, not just outcome.
De-risked bench-to-clinic and clinic-to-commercial transitions grounded in what the cells actually need at scale.
Precision profiling and design of signaling environments for cell therapy, regenerative medicine, and complex mammalian programs.
Root-cause diagnosis and process fixes for programs stuck on titer plateaus, CQA drift, or lot-to-lot variability.
Existing small-molecule modulators of your cells' actual biology — plus novel biomarker candidates for CQAs, QC panels, and process control. Discovery, not synthesis. IP in the identification and combination, not in new chemistry to qualify.
Bioprocess designs — fed-batch strategies, timing, temperature/pH staging, feed regimens — built from your cells' actual biology. IP transfers to you. Same regulatory profile as any process design decision, not a novel chemical entity.
Multi-omic profiling of your raw materials — serum lots, growth factors, ancillary reagents. Understand batch-to-batch variability at the molecular level. Backs lot qualification, process robustness, and supplier selection.
Rapid characterization on new cell systems, novel modalities, or exploratory samples — including from public data. Turn "we're not sure this will work" into "here's the mechanism, and here's what to try next."
Six ways VHL is different from every other player in this space. Each one is a category we defined or a model we brought here.
Where other digital twins model the bioreactor — and other platforms generate new molecules to add to it — ours models the biology inside your cells. Biology-first, not molecule-first. The only commercially available multi-omic cellular digital twin.
Most bioprocess models predict batch behavior from sensor data. Ours predict biological outcomes — manufacturability, potency, therapeutic quality — from the cells themselves. Category-defining platform capability.
70+ years of combined experience in bioprocessing, PD, media, reagents, and chemically-defined systems. Alumni of Eli Lilly, Roche, Sanofi, Merck KGaA, Thermo Fisher, Cytiva, and MIT. You work with them directly.
Novel formulations, feeds, and process architectures — designed from your biology — become IP advantages. All using characterized components in novel combinations. Real defensible IP without new-chemistry qualification burden. Full ingredient transparency and custom commercial pathways. Not the black-box model.
You bring the cells. We handle everything else — from multi-omic characterization through clinic-ready and commercial-scale delivery. Analytics to clinic. Analytics to commercial. One co-development engagement.
Not a media manufacturer. Not a software tool. Not a CDMO. Not a testing service. Not a shop designing new molecules for you to qualify. A biology-first cellular intelligence engine that surfaces what your cells actually need — and delivers what none of those categories alone can.
Three audiences. Three sets of questions we're built to answer.
For CHO mAb, biosimilar, biobetter, viral vector, and vaccine programs stuck on titer plateaus, CQA drift, or manufacturability issues that DoE can't crack. We surface the mechanism, deliver the fix, and hold it at scale.
For autologous, allogeneic, and regenerative programs where cellular state defines therapeutic outcome. We characterize what makes cells work — and design the media, feeds, and processes that keep them working through manufacturing and into the patient.
For E. coli, yeast, and industrial microbial programs where nutrient depletion and metabolic bottlenecks determine yield. We identify what your culture is asking for at every timepoint — and design the feed that answers.
Ranges reflect delivered outcomes across CHO, HEK, E. coli, Mv1Lu, and MSC programs. See the Customers page for detailed case studies.
NVIDIA · Microsoft · AWS · gener8tor· HudsonAlpha
Forbes · ISCT · Business Alabama · GEN · BEST STARTUPS U.S.· BioTools Innovator
Tell us about your program.
Or reach us directly at the address above. We reply within one business day.